Cabaletta Bio, Inc.
CABA
$3.51
-$0.12-3.31%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 5.83% | 23.51% | 33.31% | 44.19% | 45.24% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 37.64% | 42.72% | 49.69% | 56.58% | 67.61% |
| Operating Income | -37.64% | -42.72% | -49.69% | -56.58% | -67.61% |
| Income Before Tax | -44.87% | -52.19% | -60.35% | -64.91% | -71.21% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -44.87% | -52.19% | -60.35% | -64.91% | -71.21% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -44.87% | -52.19% | -60.35% | -64.91% | -71.21% |
| EBIT | -37.64% | -42.72% | -49.69% | -56.58% | -67.61% |
| EBITDA | -38.21% | -43.15% | -50.11% | -57.14% | -68.54% |
| EPS Basic | 2.53% | -17.76% | -42.44% | -48.12% | -41.44% |
| Normalized Basic EPS | 2.53% | -17.76% | -42.44% | -48.14% | -41.46% |
| EPS Diluted | 2.72% | -17.50% | -42.20% | -48.08% | -41.47% |
| Normalized Diluted EPS | 2.53% | -17.76% | -42.44% | -48.14% | -41.46% |
| Average Basic Shares Outstanding | 61.17% | 36.87% | 12.82% | 12.34% | 20.95% |
| Average Diluted Shares Outstanding | 61.17% | 36.87% | 12.82% | 12.34% | 20.95% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |